UPDATE 1-J&J says blood cancer drug improves progression-free survival in patients
Yahoo! Finance
Johnson & Johnson said on Friday an interim analysis showed its drug Carvykti met the main goal of improving progression-free survival in patients with a type of blood cancer in a late-stage study. The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies. Carvykti, developed by J&J and its China-focused partner Legend Biotech Corp, was approved by the U.S. health reg...
Continue Reading